Cuesta Martínez, ÁngelSuárez Porto, EduardoLarsen, MartinJensen, Kim BakSanz, LauraCompte Grau, MartaKristensen, PeterÁlvarez‐Vallina, Luis2024-02-122024-02-122006-02-16Cuesta AM, Suárez E, Larsen M, et al. Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I. Immunology. 2006;117(4):502-506. doi:10.1111/j.1365-2567.2006.02325.x0019-280510.1111/j.1365-2567.2006.02325.xhttps://hdl.handle.net/20.500.14352/101153Although DNA‐based cancer vaccines have been successfully tested in mouse models, a major drawback of cancer vaccination still remains, namely that tumour antigens are weak and fail to generate a vigorous immune response in tumour‐bearing patients. Genetic technology offers strategies for promoting immune pathways by adding immune‐activating genes to the tumour antigen sequence. In this work, we converted a model non‐immunogenic antigen into a vaccine by fusing it to domain I of the filamentous bacteriophage coat protein III gene. Vaccination with a DNA construct encoding the domain I fusion generated antigen‐specific T helper 1‐type cellular immune responses. These results demonstrate that the incorporation of protein III into a DNA vaccine formulation can modulate the gene‐mediated immune response and may thus provide a strategy for improving its therapeutic effect.engjournal article1365-2567https://doi.org/10.1111/j.1365-2567.2006.02325.xrestricted access577.1577.2DNA vaccineGenetic fusionBacteriophageBiología molecular (Farmacia)Bioquímica (Farmacia)24 Ciencias de la Vida